Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -22K | -22K | -13K | -3K | 0 |
| Operating Income | -34K | -2M | -509K | -566K | -341K |
| EBITDA | -12K | -2M | -311K | -563K | -1M |
| Net Income | -34K | -2M | -334K | -827K | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0003
+0.00% today
1Y Change
+200.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medical Cannabis Payment Solutions, Inc. (REFG) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 200.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +96.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +96.2%, free cash flow +99.4% with operating margin 0.0% and ROIC 2.3%. Stock Foundry combines REFG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REFG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REFG Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REFG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.3M
-62.1% YoY
Free Cash Flow
-$1.3M
-47.5% YoY
Revenue Growth
+0.0%
EPS Growth
+96.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -22K | -22K | -13K | -3K | 0 |
| Operating Income | -34K | -2M | -509K | -566K | -341K |
| EBITDA | -12K | -2M | -311K | -563K | -1M |
| Net Income | -34K | -2M | -334K | -827K | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 2K | 10 | 14 | 18 |
| Total Assets | 38K | 62K | 82K | 105K | 25K |
| Total Liabilities | 2M | 2M | 918K | 923K | 276K |
| Shareholder Equity | -2M | -2M | -836K | -818K | -251K |
| Total Debt | 858K | 858K | 783K | 804K | 138K |
| Net Debt | 858K | 856K | 783K | 804K | 137K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-50.3% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
1M
-47.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
1.5%
Debt / Equity
-0.37x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.